Clinical Trial

Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).

Study acronym: MosuOSSHSR
Recruiting
View on ClinicalTrials.gov →
Summary
Retrospective, multicenter observational study to evaluate the response to treatment with Mosunetuzumab in relapsed/refractory Follicular Lymphoma (FL) after at least three lines of therapy, within the Compassionate Use Program (CUP).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-09.
Status change: Not Yet Recruiting → Recruiting 2026-01-30
Trial Details
NCT Number NCT07278921
Lead Sponsor Andrés José Maria Ferreri
Conditions Relapsed/Refractory Follicular Lymphoma
Enrollment 25 participants
Start Date 2025-12-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-03